Ibex Medical Analytics is an Israeli AI-powered cancer diagnostics company.

Roche (SWX: RO), the global giant in pharmaceuticals and diagnostics, and Ibex Medical Analytics, a global leader in artificial intelligence (AI)-based cancer diagnostics, will collaborate on the development of AI-based digital pathology tools. (CISION PR Newswire)

The companies will develop an embedded image analysis workflow for pathologists to access Ibex’s AI algorithms, insights, and decision support tools using NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software.

Roche has created a Digital Pathology Open Environment that accepts third-party AI powered technological tools and which pathologists can access within Roche’s menu of AI-based image analysis tools.

Meanwhile, in June, Ibex won Breakthrough Device Designation from the US FDA for its Galen cancer detection platform. The company’s Galen Prostate and Galen Breast are the first AI-powered cancer diagnostic solutions being used in pathological labs worldwide.

A highly useful alliance for cancer diagnoses

The alliance between Ibex and Roche will enable pathologists using Roche Digital Pathology to access Ibex’s AI algorithm based tools to analyse prostate and breast biopsies.

Pathologists will therefore be able to provide accurate, efficient and timely diagnoses for their patients, particularly in cancer.

“With the addition of Ibex’s clinical-grade image analysis tools to our NAVIFY Digital Pathology menu, we can aid pathologists and providers in delivering value-based patient care by increasing their efficiency and accuracy for higher quality cancer diagnosis,” said Jill German, Head of Roche Diagnostics Pathology Customer Area.

“Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis. Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics.

Related Story: FDA Grants Breakthrough Device Designation To Israeli Startup Ibex’s AI-Powered Galen Platform For Cancer Detection